169495-51-6

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-amino-5-chloronicotinate is utilized as an intermediate in the synthesis of various pharmaceuticals for its potential pharmacological properties, contributing to the development of new drugs with improved therapeutic effects.
Used in Agrochemical Industry:
As a building block in the synthesis of agrochemicals, ethyl 2-amino-5-chloronicotinate is employed to create compounds with pesticidal or herbicidal properties, enhancing crop protection and yield.
Used in Medicinal Chemistry Research:
Ethyl 2-amino-5-chloronicotinate serves as a precursor in the synthesis of heterocyclic compounds, which are essential in the development of novel therapeutic agents with diverse applications in medicine.
Used in Chemical Synthesis:
Due to its unique chemical structure, ethyl 2-amino-5-chloronicotinate is used as a reagent in various chemical synthesis processes, facilitating the creation of complex organic molecules for a wide range of applications.

Upstream product

• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 105-56-6 ethyl 2-cyanoacetate 
• 7722-84-1 dihydrogen peroxide 

Downstream Products

• 181123-23-9 ethyl 2-amido-[N-(3-phenoxy)phenylacetyl]-5-chloronicotinate 
• 181123-22-8 ethyl 2-amido-(N-phenylacetyl)-5-chloronicotinate 

Relevant academic research and scientific papers

Access to pyridines via cascade nucleophilic addition reaction of 1,2,3-triazines with activated ketones or acetonitriles

We studied the cascade nucleophilic addition reactions of 1,2,3-triazines with activated acetonitriles or ketones, which were used to construct highly substituted pyridines that are not easily accessed by conventional methods. The strategy addressed some structural diversity issues currently facing medicinal chemistry, and the resulting pyridines could be used as convenient precursors for the synthesis of related pharmaceuticals. In particular, our method was applied to the syntheses of the marketed drug etoricoxib and several biologically important molecules in a few steps.

Synthesis method and applications of polysubstituted 2-aminopyridine derivative

The invention belongs to the field of organic synthetic chemistry, and relates to a synthetic method and applications of a polysubstituted 2-aminopyridine derivative. According to the method, a 1,2,3-triazine compound and a cyanomethyl compound are used as substrates and are subjected to a one-step cycloaddition reaction under an alkaline condition to obtain a polysubstituted 2-aminopyridine derivative, wherein the reaction does not involve in danger and control reagents and medicines, and a simple, safe, efficient and environment-friendly strategy is provided for synthesizing the polysubstituted 2-aminopyridine derivative. According to the present invention, the obtained product is subjected to further derivatization, such that the active molecule or the drug molecule containing the 2-aminopyridine structure can be synthesized, such as active molecule SC-53606, drug molecule apatinib and nevirapine.

NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel imidazo[1,2-a]pyridine cannabinoid receptor ligands, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor ligands, and uses thereof for treating diseases, conditions and/or disorders modulate by a cannab

Synthesis and SAR of 5-, 6-, 7- and 8-aza analogues of 3-aryl-4-hydroxyquinolin-2(1H)-one as NMDA/glycine site antagonists

A series of 5-, 6-, 7- and 8-aza analogues of 3-aryl-4-hydroxyquinolin-2(1H)-one was synthesized and assayed as NMDA/glycine receptor antagonists. The in vitro potency of these antagonists was determined by displacement of the glycine site radioligand [3H]5,7-dicholorokynurenic acid ([3H]DCKA) in rat brain cortical membranes. Selected compounds were also tested for functional antagonism using electrophysiological assays in Xenopus oocytes expressing cloned NMDA receptor (NR) 1A/2C subunits. Among the 5-, 6-, 7-, and 8-aza-3-aryl-4-hydroxyquinoline-2(1H)-ones investigated, 5-aza-7-chloro-4-hydroxy-3-(3-phenoxyphenyl)quinolin-2-(1H)-one (13i) is the most potent antagonist, having an IC50 value of 110 nM in [3H]DCKA binding and a Kb of 11 nM in the electrophysiology assay. Compound 13i is also an active anticonvulsant when administered systemically in the mouse maximum electroshock-induced seizure test (ED50 = 2.3 mg/kg, IP).